Senseonics Holdings Inc (NYSEAMERICAN:SENS) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 24,888,303 shares, a decline of 2.1% from the January 15th total of 25,410,985 shares. Approximately 27.4% of the shares of the company are short sold. Based on an average trading volume of 968,289 shares, the short-interest ratio is presently 25.7 days.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research cut Senseonics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 6th. Piper Jaffray Companies assumed coverage on Senseonics in a research report on Tuesday, January 29th. They set a “neutral” rating on the stock. Finally, UBS Group assumed coverage on Senseonics in a research report on Tuesday, November 27th. They set a “sell” rating on the stock. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $6.00.
Shares of NYSEAMERICAN SENS opened at $2.30 on Thursday. Senseonics has a 12 month low of $2.15 and a 12 month high of $5.29.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.chaffeybreeze.com/2019/02/14/senseonics-holdings-inc-sens-short-interest-down-2-1-in-january.html.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Featured Article: Calculate Your Return on Investment (ROI)
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.